Susquehanna International Group
KALV

Susquehanna International Group’s KalVista Pharmaceuticals KALV Stock Holding History

Susquehanna International Group’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.81M Buy
89,900
+36,200
+67% +$583K ﹤0.01% 6401
2025
Q4 		$867K Buy
53,700
+41,800
+351% +$554K ﹤0.01% 7505
2025
Q3 		$145K Sell
11,900
-258,700
-96% -$3.57M ﹤0.01% 11307
2025
Q2 		$3.06M Sell
270,600
-66,800
-20% -$817K ﹤0.01% 4924
2025
Q1 		$3.89M Buy
+337,400
New +$3.44M ﹤0.01% 4124
2024
Q3 		– Sell
-12,500
Closed -$147K – 12523
2024
Q2 		$147K Sell
12,500
-35,000
-74% -$408K ﹤0.01% 10712
2024
Q1 		$563K Sell
47,500
-240,700
-84% -$3.21M ﹤0.01% 8229
2023
Q4 		$3.53M Buy
288,200
+164,900
+134% +$1.5M ﹤0.01% 4308
2023
Q3 		$1.19M Buy
123,300
+91,700
+290% +$937K ﹤0.01% 6251
2023
Q2 		$284K Buy
+31,600
New +$291K ﹤0.01% 9550
2022
Q4 		– Sell
-96,100
Closed -$1.39M – 13062
2022
Q3 		$1.39M Sell
96,100
-1,400
-1% -$19.6K ﹤0.01% 5759
2022
Q2 		$959K Buy
97,500
+59,400
+156% +$655K ﹤0.01% 6636
2022
Q1 		$562K Buy
+38,100
New +$547K ﹤0.01% 8681
2021
Q4 		– Sell
-10,000
Closed -$175K – 13511
2021
Q3 		$175K Sell
10,000
-34,800
-78% -$705K ﹤0.01% 11638
2021
Q2 		$1.07M Sell
44,800
-16,100
-26% -$421K ﹤0.01% 7572
2021
Q1 		$1.56M Buy
60,900
+13,200
+28% +$347K ﹤0.01% 6523
2020
Q4 		$906K Buy
+47,700
New +$818K ﹤0.01% 6943

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Susquehanna International Group's KALV Position: Q1 2026 in Review

Susquehanna International Group reduced its KalVista Pharmaceuticals (KALV) stake by 35% in Q1 2026, selling an estimated $405K and leaving 46,760 shares worth $941K. The position accounts for ﹤0.01% of the portfolio, ranked #8023.

Susquehanna International Group first reported a position in KALV in Q2 2016 and has held it in 24 quarters since. The position peaked at $4.79M in Q3 2025. 184 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Susquehanna International Group held 46,760 shares of KalVista Pharmaceuticals worth $941K as of Q1 2026.
  • Susquehanna International Group sold 25,135 KalVista Pharmaceuticals shares in Q1 2026, an estimated $405K.
  • KalVista Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #8023 holding.
  • Susquehanna International Group first reported a position in KalVista Pharmaceuticals in Q2 2016 and has held it in 24 quarters since.
  • Susquehanna International Group's KalVista Pharmaceuticals position peaked at $4.79M in Q3 2025.
  • 184 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.